{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:49:56Z","timestamp":1780332596053,"version":"3.54.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet Neurology"],"published-print":{"date-parts":[[2003,10]]},"DOI":"10.1016\/s1474-4422(03)00530-1","type":"journal-article","created":{"date-parts":[[2003,9,23]],"date-time":"2003-09-23T20:53:17Z","timestamp":1064350397000},"page":"605-613","source":"Crossref","is-referenced-by-count":981,"title":["CSF markers for incipient Alzheimer's disease"],"prefix":"10.1016","volume":"2","author":[{"given":"Kaj","family":"Blennow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S1474-4422(03)00530-1_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1474-4422(03)00262-X","article-title":"Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment","volume":"2","author":"DeCarli","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib3","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(03)00530-1_bib4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/archneur.1994.00540210060013","article-title":"Clinical-neuropathological correlations in Alzheimer's disease and related dementias","volume":"51","author":"Galasko","year":"1994","journal-title":"Arch Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s004010050418","article-title":"Diagnostic accuracy of Alzheimer's disease: a clinicopathological study","volume":"91","author":"Jellinger","year":"1996","journal-title":"Acta Neuropathol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib6","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/WNL.38.11.1688","article-title":"A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques","volume":"38","author":"Davies","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(03)00530-1_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3233\/JAD-2000-23-402","article-title":"Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke","volume":"2","author":"Hesse","year":"2000","journal-title":"J Alzheimer Dis"},{"key":"10.1016\/S1474-4422(03)00530-1_bib8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0304-3940(97)00215-2","article-title":"Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease","volume":"225","author":"Otto","year":"1997","journal-title":"Neurosci Lett"},{"key":"10.1016\/S1474-4422(03)00530-1_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02815140","article-title":"Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease?","volume":"26","author":"Blennow","year":"1995","journal-title":"Mol Chem Neuropathol"},{"issue":"suppl 179","key":"10.1016\/S1474-4422(03)00530-1_bib10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1034\/j.1600-0404.107.s179.10.x","article-title":"A critical discussion of the role of neuroimaging in mild cognitive impairment","volume":"107","author":"Wolf","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/S1474-4422(03)00530-1_bib11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/089198870101400302","article-title":"One-carbon metabolism and other biochemical correlates of cognitive impairment as visualized by principal component analysis","volume":"14","author":"Gottfries","year":"2001","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1006\/exnr.2001.7814","article-title":"Cerebrospinal fluid amyloid beta(1\u201342) levels in the mild cognitive impairment stage of Alzheimer's disease","volume":"172","author":"Maruyama","year":"2001","journal-title":"Exp Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/WNL.59.4.627","article-title":"CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects","volume":"59","author":"Buerger","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(03)00530-1_bib14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1176\/appi.ajp.159.3.474","article-title":"Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's disease","volume":"159","author":"Okamura","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"suppl 179","key":"10.1016\/S1474-4422(03)00530-1_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1034\/j.1600-0404.107.s179.9.x","article-title":"Cerebrospinal fluid levels of total-tau, phospho-tau and A\u03b242 predicts development of Alzheimer's disease in patients with mild cognitive impairment","volume":"107","author":"Andreasen","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/S1474-4422(03)00530-1_bib16","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/j.1471-4159.1993.tb09823.x","article-title":"Detection of \u03c4 proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay","volume":"61","author":"Vandermeeren","year":"1993","journal-title":"J Neurochem"},{"key":"10.1016\/S1474-4422(03)00530-1_bib17","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1212\/WNL.45.4.788","article-title":"Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease","volume":"45","author":"Vigo-Pelfrey","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(03)00530-1_bib18","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer's disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1474-4422(03)00530-1_bib19","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1073\/pnas.89.7.2551","article-title":"Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients","volume":"89","author":"van Nostrand","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1474-4422(03)00530-1_bib20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0140-6736(92)91771-Y","article-title":"Low cerebrospinal-fluid concentrations of soluble amyloid beta-protein precursor in hereditary Alzheimer's disease","volume":"340","author":"Farlow","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/S1474-4422(03)00530-1_bib21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ana.410370221","article-title":"Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease","volume":"37","author":"van Gool","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/abbi.1993.1112","article-title":"Peptide composition of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease","volume":"301","author":"Miller","year":"1993","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/S1474-4422(03)00530-1_bib23","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/j.1471-4159.1993.tb09834.x","article-title":"Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue","volume":"61","author":"Roher","year":"1993","journal-title":"J Neurochem"},{"key":"10.1016\/S1474-4422(03)00530-1_bib24","series-title":"CSF: progress in Alzheimer's and Parkinson's diseases","first-page":"773","article-title":"Development of a specific diagnostic test for measurement of \u03b2-amyloid(1\u201342)","author":"Vanderstichele","year":"1998"},{"key":"10.1016\/S1474-4422(03)00530-1_bib25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ana.410380413","article-title":"Reduction of \u03b2-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease","volume":"38","author":"Motter","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib26","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1212\/WNL.54.5.1099","article-title":"Decreased beta-amyloid1\u201342 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease","volume":"54","author":"Otto","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(03)00530-1_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000048642","article-title":"Decreased CSF \u03b2-amyloid42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of \u03b2-amyloid induced by separate mechanisms","volume":"13","author":"Sj\u00f6gren","year":"2002","journal-title":"Dementia Geriatr Cogn Disord"},{"key":"10.1016\/S1474-4422(03)00530-1_bib28","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/mds.10321","article-title":"Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy","volume":"18","author":"Holmberg","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/S1474-4422(03)00530-1_bib29","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","article-title":"CSF A\u03b242 levels correlate with amyloid-neuropathology in a population-based autopsy study","volume":"60","author":"Strozyk","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(03)00530-1_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0304-3940(00)01036-3","article-title":"Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization","volume":"285","author":"Vanmechelen","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/S1474-4422(03)00530-1_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-3940(99)00476-0","article-title":"Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease","volume":"270","author":"Ishiguro","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/S1474-4422(03)00530-1_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01178-2","article-title":"Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients","volume":"287","author":"Kohnken","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/S1474-4422(03)00530-1_bib33","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0002-9440(10)62554-0","article-title":"Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay","volume":"160","author":"Hu","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","article-title":"Transient increase in CSF total tau but not phospho-tau after acute stroke","volume":"297","author":"Hesse","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1016\/S1474-4422(03)00530-1_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/sj.mp.4001220","article-title":"Phospho-tau\/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias","volume":"8","author":"Riemenschneider","year":"2003","journal-title":"Mol Psychiatry"},{"key":"10.1016\/S1474-4422(03)00530-1_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0022-510X(98)00122-1","article-title":"Combination assay of CSF tau, A beta 1\u201340 and A beta 1\u201342(43) as a biochemical marker of Alzheimer's disease","volume":"158","author":"Shoji","year":"1998","journal-title":"J Neurol Sci"},{"key":"10.1016\/S1474-4422(03)00530-1_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.410440108","article-title":"Longitudinal study of cerebrospinal fluid levels of tau, A beta1\u201340, and A beta1\u201342(43) in Alzheimer's disease: a study in Japan","volume":"44","author":"Kanai","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.50.1.169","article-title":"CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease","volume":"50","author":"Tapiola","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(03)00530-1_bib39","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0197-4580(01)00309-8","article-title":"Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group","volume":"23","author":"Shoji","year":"2002","journal-title":"Neurobiol Aging"},{"key":"10.1016\/S1474-4422(03)00530-1_bib40","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1212\/WNL.54.7.1498","article-title":"Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF","volume":"54","author":"Kahle","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(03)00530-1_bib41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0304-3940(02)01481-7","article-title":"Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease","volume":"339","author":"Sch\u00f6nknecht","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1016\/S1474-4422(03)00530-1_bib42","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1358\/mf.1998.20.3.485673","article-title":"Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan","volume":"20","author":"Nishimura","year":"1998","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib43","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1212\/WNL.54.10.1960","article-title":"Cytoskeleton proteins in CSF distinguish frontotemporal dementia from Alzheimer's disease","volume":"54","author":"Sj\u00f6gren","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(03)00530-1_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0304-3940(98)00904-5","article-title":"Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease","volume":"259","author":"Green","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/S1474-4422(03)00530-1_bib45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000051268","article-title":"The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process","volume":"12","author":"Sj\u00f6gren","year":"2001","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/S1474-4422(03)00530-1_bib46","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","article-title":"Improved discrimination of AD patients using beta-amyloid(1\u201342) and tau levels in CSF","volume":"52","author":"Hulstaert","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(03)00530-1_bib47","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s007020070079","article-title":"CSF levels of tau, \u03b2-amyloid1\u201342 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging","volume":"107","author":"Sj\u00f6gren","year":"2000","journal-title":"J Neural Transm"},{"key":"10.1016\/S1474-4422(03)00530-1_bib48","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0006-8993(99)01146-4","article-title":"Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease","volume":"823","author":"Hampel","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/S1474-4422(03)00530-1_bib49","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archneur.59.8.1267","article-title":"Differential diagnosis of Alzheimer's disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231","volume":"59","author":"Buerger","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib50","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1212\/WNL.54.9.1875","article-title":"Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies","volume":"54","author":"Kanemaru","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(03)00530-1_bib51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0304-3940(99)00845-9","article-title":"Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls","volume":"277","author":"Buerger nee Buch","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/S1474-4422(03)00530-1_bib52","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/jnnp.70.5.624","article-title":"Both total and hyperphosphorylated tau are increased in Alzheimer's disease","volume":"70","author":"Sj\u00f6gren","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S1474-4422(03)00530-1_bib53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/jnnp.60.2.237-a","article-title":"Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease","volume":"60","author":"Rosler","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S1474-4422(03)00530-1_bib54","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1468-1331.2003.00562.x","article-title":"CSF tau protein and beta-amyloid (1\u201342) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population","volume":"10","author":"Kapaki","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib55","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0304-3940(98)00781-2","article-title":"No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia","volume":"256","author":"Arai","year":"1998","journal-title":"Neurosci Lett"},{"key":"10.1016\/S1474-4422(03)00530-1_bib56","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00002093-199812000-00020","article-title":"Tau protein in cerebrospinal fluid is significantly increased at the earliest stage of Alzheimer disease","volume":"12","author":"Kurz","year":"1998","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/S1474-4422(03)00530-1_bib57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s007020170091","article-title":"Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients","volume":"108","author":"Rosler","year":"2001","journal-title":"J Neural Transm"},{"key":"10.1016\/S1474-4422(03)00530-1_bib58","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/jnnp.71.3.401","article-title":"Highly increased CSF tau protein and decreased beta-amyloid (1\u201342) in sporadic CJD: a discrimination from Alzheimer's disease?","volume":"71","author":"Kapaki","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S1474-4422(03)00530-1_bib59","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00702-002-0763-y","article-title":"CSF markers related to pathogenetic mechanisms in Alzheimer's disease","volume":"109","author":"Mulder","year":"2002","journal-title":"J Neural Transm"},{"key":"10.1016\/S1474-4422(03)00530-1_bib60","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1530-0277.1999.tb04156.x","article-title":"Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics","volume":"23","author":"Morikawa","year":"1999","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/S1474-4422(03)00530-1_bib61","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1212\/WNL.53.7.1488","article-title":"Sensitivity, specificity and stability of CSF t-tau in AD in a community-based patient sample","volume":"53","author":"Andreasen","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(03)00530-1_bib62","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp.64.3.298","article-title":"Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community-based follow-up study","volume":"64","author":"Andreasen","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S1474-4422(03)00530-1_bib63","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/WNL.58.11.1622","article-title":"Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration","volume":"58","author":"Riemenschneider","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(03)00530-1_bib64","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0304-3940(96)12810-X","article-title":"Cerebrospinal protein tau is elevated in early Alzheimer's disease","volume":"212","author":"Riemenschneider","year":"1996","journal-title":"Neurosci Lett"},{"key":"10.1016\/S1474-4422(03)00530-1_bib65","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ana.410380414","article-title":"Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease","volume":"38","author":"Arai","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib66","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0006-8993(99)01981-2","article-title":"Increased cerebrospinal fluid cAMP levels in Alzheimer's disease","volume":"846","author":"Martinez","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/S1474-4422(03)00530-1_bib67","first-page":"207","article-title":"Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease","volume":"25","author":"Munroe","year":"1995","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/S1474-4422(03)00530-1_bib68","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archneur.55.7.937","article-title":"High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype","volume":"55","author":"Galasko","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib69","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1212\/WNL.48.3.632","article-title":"Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease","volume":"48","author":"Galasko","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(03)00530-1_bib70","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s004010050418","article-title":"Diagnostic accuracy of Alzheimer's disease: a clinicopathological study","volume":"91","author":"Jellinger","year":"1996","journal-title":"Acta Neuropathol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib71","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s004010050412","article-title":"Diagnostic accuracy of Alzheimer's disease: a neuropathological study","volume":"91","author":"Kosunen","year":"1996","journal-title":"Acta Neuropathol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib72","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archneur.56.6.673","article-title":"Cerebrospinal fluid \u03b2-amyloid(1\u201342) in Alzheimer's disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease","volume":"56","author":"Andreasen","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib73","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(99)00617-5","article-title":"CSF t-tau and CSF-A\u03b242 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment","volume":"273","author":"Andreasen","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/S1474-4422(03)00530-1_bib74","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s100720170055","article-title":"CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group","volume":"22","author":"Parnetti","year":"2001","journal-title":"Neurol Sci"},{"key":"10.1016\/S1474-4422(03)00530-1_bib75","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ana.1054","article-title":"Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease","volume":"50","author":"Itoh","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib76","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1176\/appi.ajp.160.2.376","article-title":"Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231","volume":"160","author":"Buerger","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S1474-4422(03)00530-1_bib77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini Mental State\u201d A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/S1474-4422(03)00530-1_bib79","first-page":"211","article-title":"Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired patients","volume":"3","author":"Arai","year":"1997","journal-title":"Alzheimer's Res"},{"key":"10.1016\/S1474-4422(03)00530-1_bib81","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archneur.58.3.373","article-title":"Evaluation of CSF-tau and CSF-A\u03b242 as diagnostic markers for Alzheimer's disease in clinical practice","volume":"58","author":"Andreasen","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib82","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archneur.59.11.1729","article-title":"Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment","volume":"59","author":"Riemenschneider","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib83","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archneur.59.1.43","article-title":"Research evaluation and prospective diagnosis of dementia with Lewy bodies","volume":"59","author":"Lopez","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib84","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","article-title":"Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer's disease","volume":"45","author":"Price","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib85","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","article-title":"Decreased \u03b2-amyloid1\u201342 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease","volume":"289","author":"Sunderland","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/S1474-4422(03)00530-1_bib86","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1001\/jama.1956.02970070018005","article-title":"Long-term follow-up of patients who received 10,098 spinal anesthetics","volume":"161","author":"Vandam","year":"1956","journal-title":"JAMA"},{"key":"10.1016\/S1474-4422(03)00530-1_bib87","first-page":"221","article-title":"Low frequency of post-lumbar puncture headache in demented patients","volume":"88","author":"Blennow","year":"1993","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/S1474-4422(03)00530-1_bib88","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ana.111","article-title":"Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231","volume":"49","author":"Hampel","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib89","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0304-3940(02)01038-8","article-title":"Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment","volume":"333","author":"de Leon","year":"2002","journal-title":"Neurosci Lett"},{"key":"10.1016\/S1474-4422(03)00530-1_bib78","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/exnr.2000.7501","article-title":"CSF phosphorylated tau protein and mild cognitive impairment: a prospective study","volume":"166","author":"Arai","year":"2000","journal-title":"Exp Neurol"},{"key":"10.1016\/S1474-4422(03)00530-1_bib80","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000051284","article-title":"Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findings","volume":"12","author":"Lautenschlager","year":"2001","journal-title":"Dement Geriatr Cogn Disord"}],"container-title":["The Lancet Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1474442203005301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1474442203005301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:25:21Z","timestamp":1682555121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1474442203005301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":89,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["S1474442203005301"],"URL":"https:\/\/doi.org\/10.1016\/s1474-4422(03)00530-1","relation":{},"ISSN":["1474-4422"],"issn-type":[{"value":"1474-4422","type":"print"}],"subject":[],"published":{"date-parts":[[2003,10]]}}}